Immutep Limited: Surging On Positive Head And Neck Data

2025-05-08 08:46:59 ET

Summary

• Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches.
• IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues.
• Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.
• The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape.

Topline Summary and Update

Read the full article on Seeking Alpha

For further details see: